Breaking News

BioMarin Restructures ROCTAVIAN Program to Improve Profitability

Prioritizes commercial operations in the U.S., Germany and Italy while reducing additional investments in development and manufacturing.

Author Image

By: Charlie Sternberg

Associate Editor

BioMarin Pharmaceutical Inc. is updating its ROCTAVIAN business to focus commercial operations on three markets—the United States, Germany and Italy—where the medicine is approved and reimbursed as a treatment for severe hemophilia A. As a part of this change, BioMarin will adjust its ROCTAVIAN efforts across the company, reducing additional investments in development and manufacturing.   By focusing commercial, research and manufacturing programs, BioMarin anticipates reducing annual direct R...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters